 |
|
Signalife, Inc. 4705 Laurel Canyon Bl. ~ Suite 203 Studio City, CA 91607 T 864.233.2300 F 864.233.2100 http://www.signalife.com info@signalife.com |
||
PRESS RELEASE
Thursday January 18, 9:15 am ET
Signalife Cardio Gym Up and Running At Gold’s Gym
GREENVILLE, S.C., Jan. 18 /PRNewswire-FirstCall/ — Signalife, Inc. (”Company”), (AMEX:SGN) announced today that cardiac exercise testing has begun at Gold’s Gym utilizing the Company’s Fidelity 100. The testing has begun at the original Gold’s Gym in Venice Beach, California, known as the “mecca.” The test is available for all members of the Venice Beach Gold’s Gym facility and is conducted numerous times daily for a fee. The protocol for the cardiac screening exam has been established and evaluated by physicians in the area that also monitor the results for the clientele. “It is exciting to see the gym clientele embrace a better understanding of their cardiac health in an environment where they already go to exercise and to focus on their fitness. I was pleased to be onsite for the initial tests and to witness the enthusiasm expressed by the gym clientele,” stated Pamela Bunes, CEO and President of Signalife, Inc.  Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results. Caution Regarding Forward-Looking Statements Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission. |
||||